Logo

Amgen Provides Update on its Clinical Activities and Medicine Supply Amid COVID-19 Pandemic

Share this

Amgen Provides Update on its Clinical Activities and Medicine Supply Amid COVID-19 Pandemic

Shots:

  • Amgen anticipates no disruption in its supply of medicines for patients across the globe due to COVID-19 and is expected to have no shortage of its therapies
  • The company has temporarily paused the enrollment/screening in clinical studies to ensure the safety of subjects or integrity of data during a pandemic
  • Amgen reported that P-II study of AMG 510 for NSCLC- P-III study of Tezepelumab for Asthma in collaboration with AstraZeneca and P-III study of omecamtiv mecarbil for HF in collaboration with Cytokinetics are all fully enrolled- and does not anticipate any delays in obtaining results

Click here ­to­ read full press release/ article | Ref: Amgen | Image: Amgen


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions